https://academic.oup.com/ehjcimaging/article/17/12/1405/2680066?login=false
.
https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2020/08/28/16/14/EXPLORER-HCM
.
Eligible patients were randomized to mavacamten 5 mg daily (n = 123) versus placebo (n = 128) for 30 weeks.
- Total number of enrollees: 251
- Duration of follow-up: 30 weeks
- Mean patient age: 59 years
- Percentage female: 46%
- Percentage with diabetes: 5%
Inclusion criteria:
- ≥18 years of age
- Hypertrophic obstructive cardiomyopathy (left ventricular outflow tract [LVOT] gradient ≥50 mm Hg)
- LV ejection fraction (LVEF) ≥55%
- New York Heart Association (NYHA) class II-III symptoms